Renalytix PLC Management Change
18 April 2024 - 4:00PM
RNS Regulatory News
RNS Number : 0516L
Renalytix PLC
18 April 2024
Renalytix plc
("Renalytix" or the
"Company")
Renalytix Announces Management Change
- Howard Doran Promoted to President
LONDON and
SALT LAKE CITY, 18 April 2024 -
Renalytix plc
(NASDAQ: RNLX) (LSE: RENX) announces that Howard
Doran, who has served as the Company's Chief Business Officer
since September 2023, has been appointed as President, effective
April 30, 2024. Thomas McLain, who has served as the Company's
President since July 2019, is stepping down effective that
date.
James
McCullough, Renalytix CEO, said:
"We thank Tom
for his many accomplishments in helping Renalytix achieve the
tri-fecta of broad insurance coverage, FDA regulatory approval and
real-world outcomes evidence that now positions KidneyIntelX for
commercial adoption.
"Howard
assumes the position of President to lead the global sales effort
having now built our sales team from individuals with leading
industry sales track records."
For further information, please
contact:
Renalytix
plc
James McCullough, CEO
|
www.renalytix.com
Via Walbrook PR
|
|
|
Stifel
(Nominated Adviser to the Company)
Nicholas Moore / Alex Price / Nick Harland /
Samira Essebiya / Harry Billen
|
Tel: 02077107600
|
|
|
Investec Bank
plc
Gary Clarence / Shalin Bhamra
|
Tel: 020 7597 4000
|
|
|
Walbrook PR
Limited
Paul McManus / Alice Woodings / Charlotte
Edgar
|
Tel: 020 7933 8780
or renalytix@walbrookpr.com
Mob: 07980 541 893 /
07407 804 654 / 07884 664 686
|
|
|
CapComm
Partners
Peter DeNardo
|
Tel: 415-389-6400
or investors@renalytix.com
|
About
Renalytix
Renalytix (NASDAQ: RNLX) (LSE: RENX) is an
in-vitro diagnostics and laboratory services company that is the
global founder and leader in the new field of bioprognosis™ for
kidney health. The leadership team, with a combined 200+ years of
healthcare and in-vitro diagnostic experience, has designed its
KidneyIntelX laboratory developed test to enable risk assessment
for rapid progressive decline in kidney function in adult patients
with T2D and early CKD (stages 1-3). We believe that by
understanding how disease will progress, patients and providers can
take action early to improve outcomes and reduce overall health
system costs. For more information, visit www.renalytix.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
MSCIRMTTMTTBTRI
Renalytix (LSE:RENX)
Historical Stock Chart
From Apr 2024 to May 2024
Renalytix (LSE:RENX)
Historical Stock Chart
From May 2023 to May 2024